Section Arrow
ROIV.NASDAQ
- Roivant Sciences Ltd
Quotes are at least 15-min delayed:2026/03/02 08:52 EST
Pre Market
Last
 28.37
-0.57 (-1.97%)
Bid
27.85
Ask
28.8
High 29.36 
Low 28.37 
Volume 4.20K 
Regular Hours (Closed)
Last
 --
-- (--)
Day High 
-- 
Prev. Close
28.94 
1-M High
-- 
Volume 
-- 
Bid
27.85
Ask
28.8
Day Low
-- 
Open
-- 
1-M Low
-- 
Market Cap 
20.71B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA -- 
20-SMA -- 
50-SMA -- 
52-W High -- 
52-W Low -- 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.17/-1.31
Enterprise Value
20.80B
Balance Sheet
Book Value Per Share
5.97
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
29.05M
Operating Revenue Per Share
0.11
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ZYMEZymeworks-------- 
Pre Market 23.29 0 0.00%
ZVRAZevra Therapeutics-------- 
Pre Market 8.88 -0.05 -0.56%
ZURAZura Bio Limited-------- 
Pre Market 6.62 +0.005 +0.08%
ZNTLZentalis Pharmaceuticals-------- 
Pre Market 2.35 -0.04 -1.67%
ZLABZai Lab Limited-------- 
Pre Market 18.41 -0.83 -4.31%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.